2C-B (4-bromo-2,5-dimethoxyphenethylamine) is Schedule I in the United States. This means it is illegal to manufacture, buy, possess, or distribute (sell, trade, or give) without a DEA license. Not available by prescription.
Addictive Potential: None
Emergency Room Visits Yearly: No recorded hospital visits
Mandatory Minimum Sentence: Unknown
Mechanism of Action: partial agonist for 5-HT2 (5-HT2A and 5-HT2C) serotonergic receptors and a1-adrenergic receptors, among others. See more below…
2C-B (4-bromo-2,5-dimethoxyphenethylamine) is a psychedelic drug of the 2C family, an entactogen. It was first synthesized by Alexander Shulgin in 1974. In his book PIHKAL (Phenethylamines I Have Known And Loved), the dosage range is listed as 16–24 mg. 2C-B is sold as a white powder sometimes pressed in tablets or gel caps. It is usually taken orally, but sometimes is insufflated.
The graph below (Ray, 2010) shows the affinity of 2C-B for forty-two receptors, arranged in order of decreasing affinity (click the image to enlarge).
As explained by Ray (2010), “The black vertical bar represents a 100-fold drop in affinity relative to the receptor with the highest affinity. As a rule of thumb, this is presumed to be the limit of perceptible receptor interaction. Receptors to the right of the black bar should be imperceptible, while receptors to the left of the black bar should be perceptible, increasingly so the further left they are” (p. 14).
Side Effects and Adverse Reactions:
Because 2C-B is clandestinely produced, users are often unaware of the dose they are ingesting and may be surprised by the drug’s effects. Users who ingest relatively low doses of 2C-B and expect MDMA-like effects may actually experience frightening, LSD-like hallucinations. Individuals who snort 2C-B report extreme pain in their nasal passages and sinuses for up to 30 minutes after ingestion. Other side effects include nausea, muscle clenching, anxiety, and claustrophobia. Oral ingestion often results in gastrointestinal distress and increased mucus production that may result in coughing. The September 1998 Journal of Analytical Toxicology reported that very little data exist about the pharmacological properties, metabolism, and toxicity of 2C-B. The relationship between its use and disease and death are unknown (NDIC, 2001).